Pasithea value more than doubles on offering depression therapy in UK

Pasithea Therapeutics

23/11/2021 13:38

** Shares of biotech co  KTTA.O  soar 162.8% to $5.81
premarket
    ** Co says its nasal spray for treatment-resistant
depression in adults is now available in United Kingdom (https://refini.tv/3l1JYGq)
    ** Approval to provide Spravato was granted to co's
subsidiary, Pasithea Clinics, and treatment is being offered at
its Knightsbridge, London location 
    ** Co says only three clinics in the UK have been accredited
to offer this treatment
    ** Spravato is approved in the U.S., in conjunction with an
oral antidepressant, to treat adults with treatment-resistant
depression, and depressive symptoms in adults with clinical
depression with acute suicidal ideation or behavior
    ** Stock has lost ~38% since Sept 15 IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))